Consensus ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
65.49 ^USD	+2.03%		+7.82%	+18.77%

06-26	HC Wainwright Adjusts ANI Pharmaceuticals Price Target to $94 From $87, Maintains Buy Rating	MT
06-24	Top Midday Gainers	MT

Evolution of the average Target Price on ANI Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d0e6b87.xobaYYt5jpo1eEn0obvcmzfgwRuYdP8M34avfLemcH4.g--8Gf0TxdVdMwyTks-yo0KCuX7fE8hijeL1I8WQFSeOyL81s0z3yGA6Pg~de67ee515de7c9301f80ae21819afdea

Analyst Recommendations on ANI Pharmaceuticals, Inc.

HC Wainwright Adjusts ANI Pharmaceuticals Price Target to $94 From $87, Maintains Buy Rating	06-26	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,817,663, According to a Recent SEC Filing	06-21	MT
Ani Pharmaceuticals Insider Sold Shares Worth $317,900, According to a Recent SEC Filing	06-06	MT
ANI Pharmaceuticals Insider Sold Shares Worth $1,288,200, According to a Recent SEC Filing	06-05	MT
Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing	05-21	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing	05-16	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing	05-03	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	04-17	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing	04-03	MT
Capital One Initiates ANI Pharmaceuticals at Overweight Rating	03-15	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating	03-05	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating	03-04	MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating	03-01	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $72 From $70, Maintains Buy Rating	02-16	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $73 From $60, Maintains Buy Rating	23-08-22	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $62 From $59, Keeps Buy Rating	23-07-27	MT
Truist Adjusts ANI Pharmaceuticals' Price Target to $60 From $52, Keeps Buy Rating	23-07-21	MT
Guggenheim Adjusts Price Target on ANIP to $59 From $55, Maintains Buy Rating	23-05-09	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $52 From $50, Maintains Buy Rating	23-05-09	MT
Raymond James Adjusts Price Target on ANI Pharmaceuticals to $49 From $48, Maintains Outperform Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $60 From $53, Keeps Buy Rating	23-05-09	MT
Cantor Fitzgerald Adjusts ANI Pharmaceuticals Price Target to $42 From $40, Maintains Neutral Rating	23-05-08	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $53 From $50, Keeps Buy Rating	23-03-13	MT
HC Wainwright Starts ANI Pharmaceuticals at Buy With $50 Price Target	22-09-07	MT
S&P Revises ANI Pharmaceuticals Outlook To Stable From Positive On Increased Expenses; 'B+' Ratings Affirmed	22-08-29	MT